Study of an experimental treatment for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests an experimental treatment (LY3962681) for people with early Parkinson's. It aims to see if the treatment is safe and can slow the disease. You must have a confirmed diagnosis, be in good overall health, and have stable medication use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally in good health aside from Parkinson's disease.
- You have early-stage Parkinson's (modified Hoehn and Yahr stage 1 to 2.5 when off medication).
- You have a positive spinal fluid test for alpha-synuclein clumps or an abnormal DaTscan that supports the diagnosis.
- Your Parkinson's medications (if any) have been stable for at least 8 weeks, and you can likely go without changing them for 6 months.
- You weigh between 88 and 242 pounds (40 to 110 kg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This trial tests a new treatment called DSP-1083 for people with Parkinson's disease whose symptoms are not well controlled with standard medications. The study will check if it is safe and if it helps improve movement and daily function.
This trial tests an investigational drug called IPS101A in people with advanced Parkinson's disease. It aims to see if the drug is safe and how well it works when standard treatments are no longer enough.
This trial tests an experimental drug called MT101-5 for people recently diagnosed with Parkinson's disease. It aims to see if the drug is safe and can help control symptoms.
This study looks at a new pump treatment (foslevodopa/foscarbidopa) for people with advanced Parkinson's who are having motor fluctuations. It aims to see if it improves quality of life when started earlier in the advanced stage.
This trial tests a new experimental drug called ALN-SNCA, given as an injection into the spinal fluid, for people with early Parkinson's disease. The goal is to see if it is safe and well-tolerated.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.